Stock News

Eli Lilly to create 100 jobs in Indianapolis as it adds capacity to its technology center campus
Lilly announces $400 million capital investment in manufacturing facilities in Indianapolis
Lilly Confirms Date and Conference Call for 2020 Financial Guidance Announcement
Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug
Supernus Pharmaceuticals seeks FDA approval for ADHD drug
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
Eli Lilly Has the Base to Support a New Rally

As seen on...